Shots:
- VectorY has entered into an option & license deal with Shape to assess Shape’s SHP-DB1 (AAV capsid) for vectorized Abs payloads against 3 targets & may secure an exclusive license for their delivery if evaluation succeeds
- As per the deal, VectorY will handle development & commercialization of resulting therapies in exchange for an upfront payment, plus ~$1.2B in fees & milestones, incl. ~$338M for rare disease & $503.5M for non-rare disease programs, along with tiered royalties on future sales
- Collaboration will enable IV delivery across VectorY’s pipeline, incl. VTx-003 for Huntington’s disease (IND & CTA submissions planned for 2025, with trial starting in early 2026) & VTx-005 for Alzheimer’s Disease
Ref: VectorY Therapeutics | Image: VectorY Therapeutics and Shape Therapeutics | Press Release
Related News:- VarmX Inks a ~$2.2B Strategic Collaboration and Option Agreement with CSL for VMX-C001 to Advance Coagulation Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
